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Aggregation of amyloid-b (Ab) peptide into soluble
and insoluble forms within the brain extracellular
space is central to the pathogenesis of Alzheimer’s
disease. Full-length amyloid precursor protein (APP)
is endocytosed from the cell surface into endosomes
where it is cleaved to produce Ab. Ab is subsequently
released into the brain interstitial fluid (ISF). We
hypothesized that synaptic transmission results in
more APP endocytosis, thereby increasing Ab gener-
ation and release into the ISF. We found that inhibition
of clathrin-mediated endocytosis immediately lowers
ISF Ab levels in vivo. Two distinct methods that
increased synaptic transmission resulted in an eleva-
tion of ISF Ab levels. Inhibition of endocytosis, how-
ever, prevented the activity-dependent increase in
Ab. We estimate that 70% of ISF Ab arises from
endocytosis-associated mechanisms, with the vast
majority of this pool also dependent on synaptic ac-
tivity. These findings have implications for AD patho-
genesis and may provide insights into therapeutic
intervention.
INTRODUCTION
Extracellular aggregation and accumulation of the amyloid-b (Ab)
peptide in different forms, including plaques within the hippo-
campus and neocortex, is one hallmark pathology of Alzheimer’s
disease (AD) (Selkoe, 2001). Within the brain, Ab is primarily
produced within neurons by cleavage of the amyloid precursor
protein (APP) followed by secretion into the brain interstitial fluid
(ISF). Within the ISF, Ab is found in its normal, soluble form
throughout life. During the pathogenesis of AD, Ab aggregates
into forms that include insoluble species and probably soluble
Ab oligomers, both of which have been demonstrated under par-42 Neuron 58, 42–51, April 10, 2008 ª2008 Elsevier Inc.ticular circumstances to be toxic to cells or to disrupt synaptic
plasticity. While the initial polymerization seed for Ab aggregates
may form intracellularly or extracellularly (Gouras et al., 2000;
Meyer-Luehmann et al., 2003), it is likely that much of the peptide
necessary for Ab aggregation as well as plaque formation and
growth is derived from the soluble ISF pool of Ab. Conversion
of soluble Ab into either plaques or oligomers is concentration
dependent, meaning that elevated levels of ISF Ab are likely to
hasten the formation of these toxic species. Consequently,
knowing the factors that regulate ISF Ab levels has implications
for understanding disease pathogenesis as well as for develop-
ing therapeutics.
Although molecular events surrounding secretase cleavage of
APP are well understood, the cellular processes regulating Ab
production and the subsequent release of Ab by neurons are
less characterized. Neuronal activity modulates Ab levels. Activa-
tion of muscarinic M1 acetylcholine receptors increases a-secre-
tase cleavage of APP and consequently reduces Ab levels in
animal models as well as in humans (Caccamo et al., 2006; Nitsch
et al., 2000). Activation of NMDA receptors decreases a-secre-
tase cleavage, thereby increasing Ab levels (Lesne et al., 2005).
Lesions of the cortical axon fibers that project to the dentate
gyrus substantially reduce Ab accumulation in APP transgenic
mice (Lazarov et al., 2002; Sheng et al., 2002). Additionally, mod-
ulating synaptic transmission alters extracellular soluble Ab levels
in organotypic brain slice (Kamenetz et al., 2003). Using APP
transgenic and wild-type mice, our group demonstrated that
synaptic activity dynamically modulates ISF Ab levels in vivo
(Cirrito et al., 2005). Hippocampal seizures induced by electrical
stimulation increased ISF Ab levels by 30% within 30 min. Con-
versely, decreasing synaptic transmission using tetrodotoxin
(TTX) or tetanus toxin rapidly reduced ISF Ab levels by 30% and
80%, respectively.
In acute brain slices, synaptic vesicle cycling alone, in the ab-
sence of neuronal depolarization, was sufficient to drive release
of Ab from neurons (Cirrito et al., 2005). Because Ab is not lo-
cated within synaptic vesicles (Ikin et al., 1996; Marquez-Sterling
et al., 1997), we hypothesized that an event closely associated
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responsible for Ab production and release from neurons. Cell
culture experiments have shown that full-length APP is retrieved
from the cell surface via clathrin-mediated endocytosis (Nord-
stedt et al., 1993), then APP is cleaved by b-secretase (BACE)
and g-secretase within late and early endosomes to produce
Ab (Lah and Levey, 2000; Vassar et al., 1999). Ab produced in
the endocytic pathway is then brought to the cell surface where
it is released into the extracellular fluid (Koo et al., 1996). Inhibi-
tion of endocytosis reduces APP internalization and reduces Ab
production and release in cell lines (Carey et al., 2005; Koo and
Squazzo, 1994). During synaptic transmission, synaptic vesicles
fuse with the plasma membrane, followed by the synaptic vesicle
membrane being retrieved from the cell surface, at least in part
via clathrin-mediated endocytosis (Maycox et al., 1992). Within
synaptosomes, clathrin-coated vesicles contain APP as well as
several synaptic vesicle proteins, including synaptophysin,
synaptotagmin I, and SV2 (Marquez-Sterling et al., 1997). This
suggests that synaptic proteins and APP can be internalized
from the plasma membrane together via a common pathway.
Because synaptic activity leads to elevated endocytosis of
synaptic vesicle-related proteins, we hypothesized a synaptic
activity-induced increase in endocytosis also drives more APP
into the endocytic compartment, ultimately resulting in increased
Ab production and release. Herein, we provide direct evidence
for this hypothesis in the brain in vivo.
RESULTS
Ab is primarily produced within neurons and secreted into the
brain ISF. In order to assess ISF Ab levels in living mice, we
utilized an in vivo microdialysis technique that enables serial sam-
pling of molecules within the brain ISF (Cirrito et al., 2003). Micro-
dialysis probes were implanted unilaterally into the hippocampus
of 3-month-old Tg2576 APP transgenic mice (Hsiao et al., 1996).
Following probe implantation under volatile anesthesia, mice
remained awake with freedom of movement throughout the ex-
periment. ISF Ab levels were assessed every 30–60 min for up
to 24 hr, enabling us to determine basal ISF Ab levels and then in-
tervene pharmacologically to assess the effect on ISF Ab levels
over time within the same mouse. In addition to measuring Ab
levels, microdialysis also permits the direct administration of
small molecular weight compounds into the hippocampus via
reverse microdialysis. Using this procedure, we administered
compounds to the exact region of tissue from which Abwas sam-
pled. In a subset of mice, dual recording electrodes were at-
tached to the microdialysis probe assembly to record electrical
field potentials near sites of Abmeasurement (Cirrito et al., 2005).
Inhibition of Endocytosis Reduces ISF Ab Levels In Vivo
We hypothesized that Ab released into the brain ISF following
synaptic transmission requires an intermediate event involving
APP endocytosis. We first assessed the influence of endocytosis
on ISF Ab levels under normal conditions. A dynamin dominant-
negative inhibitory peptide (dynamin-DN) was infused directly
into the hippocampus by reverse microdialysis. Dynamin-DN
blocks dynamin binding to amphiphysin, thus inhibiting scission
of clathrin-coated vesicles from the plasma membrane. Thismyristylated, cell-permeable peptide has been shown in cell cul-
ture to inhibit clathrin-mediated endocytosis (Marks and McMa-
hon, 1998). In vivo, dynamin-DN reduced biotinylated transferrin
uptake into cells within the dentate gyrus, confirming the in vivo
effectiveness of this peptide at reducing endocytosis (see
Figure S1 available online).
Basal ISF Ab levels were established in 3-month-old Tg2576
APP transgenic mice over 8 hr, followed by 4 hr of continuous ad-
ministration of dynamin-DN (Figure 1A). At this age, Tg2576 mice
do not contain Ab deposits, and Ab metabolism can be studied
without the complicating factor of Ab aggregates (Hsiao et al.,
1996). Within 30 min of dynamin-DN treatment, ISF Ab levels
were significantly decreased, with a maximal decrease of 70%
by hour four of treatment (Figure 1A). This is similar to studies in
cell culture demonstrating that inhibition of endocytosis reduces
Ab levels in media (Koo and Squazzo, 1994). Following treatment,
dynamin-DN was removed from the microdialysis perfusion
buffer, and ISF Ab levels were measured for an additional 8 hr.
Within 2 hr of washout, Ab levels increased transiently by 250%
over baseline levels and returned to basal levels within 8 hr. ISF
Ab levels did not change significantly in mice treated with vehicle
or in mice treated with 200 mM scrambled peptide (Figure 1A).
Similarly, ISF levels of the neuropeptide orexin (also called hypo-
cretin) were also unchanged in response to dynamin-DN infusion
(see Figure S2 available online).
To determine the dose of dynamin-DN that maximally reduces
ISF Ab levels in vivo, Tg2576 mice were administered a dose es-
calation of inhibitory peptide (Figure 1B). Dynamin-DN had an
IC50 of 100.4 ± 5.9 mM in vivo, with a dose of 200 mM maximally
reducing ISF Ab levels (Figure 1C). These data demonstrate that
inhibition of clathrin-mediated endocytosis can dramatically
reduce ISF Ab levels in vivo.
To assess the effect of dynamin-DN on cell-surface APP
levels, we treated a Neuro2A (N2A) neuroblastoma cell line that
expresses APP695 (Thinakaran et al., 1996) with dynamin-DN
or a myristylated, scrambled control peptide for 4 hr. Inhibition
of endocytosis increased cell-surface APP fluorescence by
50% compared to the control peptide treatment (Figure S3A).
Dynamin-DN treatment did not alter total APP expression levels
in this cell line; however, it significantly reduced APP b-CTF
levels (Figure S3B). Dynamin-DN also significantly decreased
Ab levels within the cells by 30% (Figure S3C). Consistent with
the effects of dynamin-DN, another less specific inhibitor of cla-
thrin-mediated endocytosis, chlorpromazine (Wang et al., 1993),
reduced ISF Ab levels in vivo by 20% (Figure S4). Together, the
data demonstrate that dynamin-DN reduces APP endocytosis,
cleavage by b-secretase, and thus Ab generation.
Inhibition of Endocytosis Does Not Depress
Synaptic Transmission
Clathrin-mediated endocytosis is required for a variety of cellular
functions, including, in part, the recycling of synaptic vesicle
membrane in order to replenish the readily releasable pool of syn-
aptic vesicles (Heuser and Reese, 1973). Inhibition of dynamin
can deplete synaptic vesicles (Newton et al., 2006). Interestingly,
genetic deletion of dynamin I in mice does not affect spontaneous
synaptic transmission; however, it can result in depressed
evoked postsynaptic potentials, especially following trains ofNeuron 58, 42–51, April 10, 2008 ª2008 Elsevier Inc. 43
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Synaptic-Dependent Ab Release Requires EndocytosisFigure 1. Inhibition of Endocytosis Reduces ISF Ab Levels
(A) In vivo measurement of ISF Ab levels during inhibition of endocytosis in 3-month-old Tg2576 mice. Infusion of a dynamin-DN inhibitory peptide (200 mM) into
the hippocampus via reverse microdialysis reduced ISF Ab1-x levels to 36.1% ± 4.2% of baseline levels over 4 hr (p < 0.0001, n = 9 per group). When dynamin-DN
was removed from the microdialysis perfusion buffer, ISF Ab levels increased transiently by 246.7% ± 20.7% compared to baseline (p < 0.0001) and returned to
basal levels by 8 hr of washout. ISF Ab levels did not change significantly over the course of the study in either untreated mice or in mice treated with 200 mM
scrambled peptide.
(B) A dose escalation of dynamin-DN demonstrated a maximum reduction of ISF Ab levels with a dose of 200 mM of inhibitory peptide (p < 0.0001, n = 3).
(C) Final Ab levels achieved during each epoch depicted in (B).
(D–F) EEG recordings during basal and dynamin-DN administration. (D) Representative EEG traces during basal and dynamin-DN treatment. EEG amplitude stan-
dard deviation (E) and frequency (F) were not significantly different when endocytosis was inhibited (n = 3).
(G–I) Evoked fEPSPs from dentate gyrus during basal and dynamin-DN treatment. (G) Representative fEPSP traces elicited by medial perforant pathway stim-
ulation. Arrow denotes initial fEPSP slope. (H) The initial slope of the fEPSP did not change during 4 hr of dynamin-DN treatment; however, when the perfusion
buffer was changed to contain 10 mM TTX, the fEPSP was significantly reduced by 89.8% ± 3.8% within 15 min of treatment (p < 0.0001, n = 3). (I) Likewise, fEPSP
slope was similar under basal and dynamin-DN treatment during 1 Hz trains of stimuli for 60 s (n = 3). Data presented as mean ± SEM. **p < 0.001, ***p < 0.0001.strong exogenous stimuli (Ferguson et al., 2007). Because
depressed synaptic activity reduces Ab release (Cirrito et al.,
2005; Kamenetz et al., 2003), it is conceivable that dynamin-DN
may reduce ISF Ab levels by inhibiting synaptic activity and not
necessarily by having a direct effect on APP endocytosis or Ab
generation. In order to test this possibility during inhibition of
endocytosis, we assessed neuronal activity using spontaneous
field potential recordings as well as evoked potential recordings.
Dual recording electrodes assessed extracellular field poten-
tials, or depth EEG, within the hippocampus at the same location
that Ab was measured and that dynamin-DN was administered
(Figure 1D). Inhibition of endocytosis did not alter the amplitude
(Figure 1E) or frequency (Figure 1F) of EEG activity within the hip-
pocampus at any point during administration. Mice remained
awake with freedom of movement throughout these recordings.44 Neuron 58, 42–51, April 10, 2008 ª2008 Elsevier Inc.Therefore, these results suggest that global neurotransmis-
sion was not dramatically altered by dynamin-DN at the doses
utilized.
EEG records spontaneous, physiological neuronal activity
within a large volume of brain tissue and may not be sensitive
to subtle, local changes in activity. Consequently, we assessed
evoked field EPSPs (fEPSPs), which provides a more direct
assessment of synaptic transmission within the hippocampus
in an awake, behaving animal. Bipolar stimulating electrodes
were implanted into the medial perforant pathway. In the same
animal, a microdialysis probe with dual recording electrodes
was implanted into the dentate gyrus, enabling evoked fEPSP
measurement and local dynamin-DN administration (Figure 1G).
Dynamin-DN did not change the initial slope of the fEPSP mea-
sured at either 15 min, 2 hr, or 4 hr of administration compared to
Neuron
Synaptic-Dependent Ab Release Requires EndocytosisFigure 2. Activity-Dependent Release of Ab
Requires Endocytosis
(A) ISF Ab levels in Tg2576 mice treated with vehi-
cle or 200 mM dynamin-DN followed by 25 mM
picrotoxin via reverse microdialysis to increase
neuronal activity (n = 4 per group).
(B) Picrotoxin alone increased ISF Ab levels by
145.5% ± 6.8% averaged over 4 hr of administra-
tion (p < 0.01). Pretreatment with 200 mM dynamin-
DN prevented the increase in ISF Ab levels caused
by picrotoxin.
(C) Representative EEG traces during basal condi-
tions and during picrotoxin treatment with and
without dynamin-DN administration. This low
dose of picrotoxin did not generate seizures in
any of the mice tested, but consistently caused
synchronous spikes in EEG activity (arrows) in
the presence and absence of dynamin-DN.
(D) EEG amplitude increased similarly in picro-
toxin-treated mice administered vehicle or dyna-
min-DN. Data presented as mean ± SEM.
**p < 0.001, ***p < 0.0001.basal recordings from the same mouse (Figure 1H). Given that
dynamin-DN produced a negative result, we sought to confirm
that a change in fEPSP could be detected if an appropriate
compound was infused into the brain. Following dynamin-DN
administration, the perfusion buffer was changed to contain te-
trodotoxin (TTX), a sodium channel blocker that should potently
inhibit evoked fEPSPs. Within 15 min of TTX treatment, the
fEPSP slope was reduced by 95% and was undetectable by
1 hr of treatment. Single fEPSPs were not inhibited by dyna-
min-DN, so we also determined if trains of stimuli could elicit a
difference in fEPSP slope. Stimuli at 1 Hz for 60 s also did not
result in a difference in the evoked EPSP slope between basal
and dynamin-DN conditions (Figure 1I). The reduction in fEPSP
slope in both groups over the course of the train is typical for
this type of recording using medial perforant pathway stimulation
(McNaughton, 1980). Given that neither spontaneous EEG activ-
ity nor evoked fEPSPs were altered in the presence of dynamin-
DN, it does not appear that inhibition of endocytosis substantially
affects synaptic transmission in vivo at normal, spontaneous
levels or at low frequencies of stimulation. These data suggest
that the small, remaining portion of clathrin-mediated endocyto-
sis is capable of sustaining normal synaptic transmission or that
some dynamin-1-independent mechanisms of vesicle retrieval
are active (Ferguson et al., 2007). It appears from our data that
administration of dynamin-DN does not adversely affect in vivo
synaptic transmission over the timescale that we assessed.
Activity-Dependent Elevation of ISF Ab
Levels Requires Endocytosis
Synaptic transmission dynamically modulates ISF Ab levels
in vivo. Depression of synaptic activity reduces ISF Ab levels
whereas seizures rapidly increase Ab levels in Tg2576 mice
(Cirrito et al., 2005). We sought to determine if subtle increases
in synaptic transmission could also elevate ISF Ab levels and if en-
docytosis was required for the activity-dependent Ab production
and release. Tg2576 mice were treated with 25 mM picrotoxin,a noncompetitive GABAA receptor antagonist, via reverse micro-
dialysis (Figure 2A). Picrotoxin caused a significant 50% increase
in ISF Ab levels by 4 hr of administration (Figure 2B). In contrast,
dynamin-DN reduced ISF Ab levels and prevented the increase
in Ab levels when coadministered with picrotoxin. While high
doses of picrotoxin can generate seizures, the low dose used
here only produced occasional spikes in synchronous EEG activ-
ity (Figure 2C). Similar spikes in EEG activity also occurred during
dynamin-DN and picrotoxin coadministration. As a consequence
of picrotoxin treatment, the amplitude of EEG activity increased
similarly inbothdynamin-DNand vehicle-treatedmice (Figure2D).
Metabotropic glutamate receptors 2/3 (mGluR2/3) are ex-
pressed presynaptically to modulate glutamate release. When
these receptors are inhibited, glutamate release from the presyn-
aptic terminal is enhanced (Losonczy et al., 2003). LY341495,
a mGluR2/3 antagonist, was administered directly into the hip-
pocampus to increase synaptic activity during microdialysis to
determine the effect on ISF Ab levels (Figure 3A). LY341495
caused a gradual increase in ISF Ab levels to 20% of baseline
over 8 hr (Figure 3B). In the presence of LY341495 and dyna-
min-DN, Ab levels were not increased compared to dynamin-
DN alone. The effects of both picrotoxin and LY341495 on ISF
Ab levels were prevented by inhibiting endocytosis. This sug-
gests that endocytosis was a key event linking elevated synaptic
activity and release of Ab into the brain ISF in Tg2576 mice.
One concern regarding any transgenically expressed protein is
that it could be regulated and processed differently than the en-
dogenous protein. Consequently, we assessed the link between
synaptic activity, endocytosis, and murine ISF Ab40 and Ab42
levels in 3-month-old C57Bl6 wild-type mice. Because murine
Ab levels are substantially lower and more difficult to detect
than human Ab in Tg2576 mice, we sampled ISF Ab levels over
12 hr periods instead of every 30 min (Figure 4). Similar to
Tg2576 mice, 25 mM picrotoxin increased murine ISF Ab40 and
Ab42 levels by 130% over baseline. Dynamin-DN reduced ISF
Ab40 and Ab42 levels by 60% and 75%, respectively. Interestingly,Neuron 58, 42–51, April 10, 2008 ª2008 Elsevier Inc. 45
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Elevates ISF Ab Levels, which Requires
Endocytosis
(A) ISF Ab levels in Tg2576 mice treated with dyna-
min-DN or vehicle followed by LY341495, an
mGluR2/3 antagonist that increases presynaptic
glutamate release.
(B) LY341495 increased ISF Ab levels by 122.2% ±
8.4% during hours 6–8 of treatment (p < 0.05,
n = 4). The increase in Ab levels was prevented
by pretreatment with dynamin-DN (n = 4). Data
presented as mean ± SEM. *p < 0.05.the greater decrease in Ab42 than Ab40 was statistically signifi-
cant. A subset of mice was pretreated with dynamin-DN for
1 hr, then coadministered picrotoxin for 12 hr. Ab levels in these
mice were not statistically different than those treated with dyna-
min-DN alone. That endocytosis is a key event linking synaptic
activity and Ab generation in wild-type mice underscores that
this phenomenon is part of a normal pathway for Ab production.
Inhibition of Endocytosis Does Not
Affect ISF Ab Elimination
It is possible that inhibition of endocytosis could affect both ISF
Ab production and ISF Ab elimination. In the case of Ab produc-
tion, endocytosis is required for internalization of full-length
APP prior to Ab generation (Koo and Squazzo, 1994). In the
case of elimination, molecules such as LRP1 have been shown
to internalize Ab directly or bound to apoE (Deane et al., 2004).
In order to determine if inhibition of endocytosis modulates ISF
Ab elimination, we measured the half-life of ISF Ab in Tg2576
Figure 4. Endocytosis Is Required for Activity-Dependent Release of
Endogenous Murine Ab
In C57Bl6 mice, 25 mM picrotoxin increased ISF murine Ab40 and Ab42 levels to
133.4% ± 2.3% and 131.5% ± 6.1%, respectively (p < 0.0001), of baseline
over 12 hr. Two-hundred micromolar dynamin-DN reduced murine Ab40 levels
to 38.3% ± 2.8% (p < 0.0001) and Ab42 levels to 23.8% ± 0.8% of baseline
(p < 0.0001). Ab42 levels were significantly more reduced than Ab40 levels
(p < 0.0001; noted by ###). Pretreatment with dynamin-DN for 1 hr then coad-
ministration of dynamin-DN and picrotoxin caused ISF Ab40 and Ab42 levels to
decrease to 43.9% ± 3.7% and 18.9% ± 1.5% of baseline, which was not
statistically different from dynamin-DN treatment alone. n = 6 per group.
Data presented as mean ± SEM. ***p < 0.0001.46 Neuron 58, 42–51, April 10, 2008 ª2008 Elsevier Inc.mice treated with vehicle or dynamin-DN. Basal ISF Ab levels
were determined, followed by administration of dynamin-DN or
vehicle for 4 hr, after which mice were injected with a potent
g-secretase inhibitor (LY411575) subcutaneously to rapidly in-
hibit g-secretase activity and Ab production (Figure 5A) (Cirrito
et al., 2003). ISF Ab elimination followed first-order kinetics in
both vehicle and dynamin-DN treated mice (Figure 5B). The
half-life of ISF Ab was approximately 1 hr in both groups (Fig-
ure 5C), which is similar to previously published values for this
mouse model (Cirrito et al., 2005; Yin et al., 2006). This demon-
strates that dynamin-DN does not dramatically affect ISF Abelim-
ination. Though this assay may be insensitive to subtle changes in
Ab elimination, it suggests that inhibition of endocytosis alters ISF
Ab levels via changes in Abproduction and release following APP
internalization and not via changes in Ab clearance.
Distinct Pathways for ISF Ab Generation
Both inhibition of synaptic activity (Cirrito et al., 2005) and inhibi-
tion of endocytosis reduce ISF Ab levels. In order to determine
the extent that activity and endocytosis each contribute to ISF
Ab levels, we coadministered TTX and dynamin-DN. If dyna-
min-DN was administered first, ISF Ab levels declined by a max-
imum of 70% (Figures 6A and 6B). If the microdialysis perfusion
buffer was then switched to contain dynamin-DN and TTX, there
was no additional change in ISF Ab levels. This suggests that all
of the ISF Ab that is produced due to synaptic activity requires
endocytosis. Conversely, if animals were pretreated with TTX,
followed by dynamin-DN coadministration, then ISF Ab levels
were further reduced when endocytosis was inhibited (Figures
6C and 6D). This demonstrates that there is a pool of ISF Ab
that is generated via endocytosis that is not affected by synaptic
activity but remains sensitive to dynamin-DN.
DISCUSSION
Many studies have postulated that the aggregation of Ab in both
soluble and insoluble forms in the brain is likely a key initiating
factor in AD pathogenesis. Thus, influences on the aggregation
process are potentially major treatment targets. Since the pro-
cess of Ab aggregation is concentration dependent, understand-
ing factors that regulate Ab levels in the location that it aggre-
gates (e.g., in the brain extracellular space) is likely to provide
critical insights into the biology of AD. While it has been demon-
strated that APP endocytosis is a key step in Ab generation and
Neuron
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clathrin-mediated endocytosis reduces ISF Ab levels in awake
mice, both transgenic and wild-type, under normal conditions.
Importantly, in addition to endocytosis, our work shows that syn-
aptic activity, and specifically synaptic vesicle exocytosis, is
linked with neuronal Ab release. Utilizing two distinct pharmaco-
logical interventions, we found that increasing synaptic activity
increases ISF Ab levels in a manner dependent on endocytosis.
Clathrin-mediated endocytosis of APP is necessary for activity-
dependent regulation of ISF Ab levels in APP transgenic mice
as well as in wild-type mice. This emphasizes that these results
elucidate a normal pathway for regulating ISF Ab levels. Block-
ade of endocytosis primarily affected Ab generation with no
detectable change in ISF Ab elimination. We estimate that the
majority of ISF Ab in vivo is generated through endocytosis of
Figure 5. Dynamin-DN Does Not Affect ISF Ab Elimination
(A) Hippocampal ISF Ab levels were measured in Tg2576 mice that were
treated with vehicle or 200 mM dynamin-DN, followed by 3 mg/kg LY411575
s.c. to inhibit g-secretase activity (n = 4–6 per group).
(B) Plots of log % basal ISF Ab levels were linear in both vehicle and dynamin-
DN-treated mice, demonstrating first-order kinetics of ISF Ab elimination in
both groups.
(C) The elimination half-life of ISF Ab (calculated from the slope in panel [B])
was the same in vehicle and dynamin-DN-treated mice (1.1 ± 0.24 hr and
1.2 ± 0.27 hr, respectively). Data presented as mean ± SEM.APP and that, in the brain, synaptic activity plays a primary
role in that process. Overall, these findings define a pathway
by which synaptic activity influences Ab release into brain ISF
that is likely relevant to AD pathogenesis.
One major pathway for Ab generation is endocytosis of full-
length APP from the plasma membrane into the endocytic com-
partment, where BACE and g-secretase act to produce Ab. Ab is
then subsequently secreted from the neuron into the extracellu-
lar space. Our hypothesis is that synaptic activity drives more
APP into the endocytic compartment, thus increasing Ab gener-
ation and release. Action potential invasion of the synaptic termi-
nal causes calcium influx (Figure 7A). Calcium causes synaptic
vesicles to fuse with the plasma membrane and to release neu-
rotransmitter into the synaptic cleft (Figure 7B). This is the basis
of synaptic transmission. As more synaptic vesicles fuse with the
plasma membrane, there is an increase in the amount and overall
rate of endocytosis that recycles the vesicular membrane from
the cell surface. When the synaptic vesicle membrane is re-
cycled from the plasma membrane via clathrin-mediated endo-
cytosis, more APP is internalized as well (Figure 7C). It is possible
that calcium entry may also cause endocytosis through other
mechanisms, such as synthesis of PI(4,5)P2, which recruits the
clathrin assembly and mediates clathrin-mediated endocytosis
(Wenk et al., 2001). Increased endocytosis increases APP inter-
nalization into the endocytic compartment where Ab is gener-
ated (Figure 7D). Once generated, Ab can be secreted from the
neuron into the brain extracellular space (Figure 7E).
Our previous studies provide direct evidence that Ab is gener-
ated due to presynaptic mechanisms; causing synaptic vesicle
exocytosis with a-latrotoxin in the absence of postsynaptic acti-
vation is still capable of generating Ab (Cirrito et al., 2005). We
cannot rule out a postsynaptic mechanism as well, however.
a-Latrotoxin in the presence of postsynaptic activation has
a greater effect on extracellular Ab than a-latrotoxin in the ab-
sence of the postsynaptic activation. The difference between
these two conditions (20% of Ab generation) is likely due to
postsynaptic mechanisms that also influence Ab generation
(Cirrito et al., 2005).
Two mechanistically distinct agents increased synaptic activ-
ity and increased ISF Ab levels. Picrotoxin inhibits ionotropic
GABAA receptors, thus increasing synaptic transmission by
reducing inhibition of excitatory neurons. In contrast, LY341495
blocks perisynaptic G protein-coupled mGluR2/3, thus increas-
ing excitatory neurotransmission by directly enhancing gluta-
mate release at the synapse. Both of these pathways increased
Ab levels by modestly increasing synaptic activity. In both cases,
inhibition of endocytosis completely blocked the elevation of the
ISF Ab levels. This phenomenon was also observed with wild-
type murine Ab40 and Ab42 levels. Interestingly, inhibition of en-
docytosis had a larger effect on Ab42 levels than Ab40, perhaps
suggesting that a greater percentage of extracellular Ab42 comes
from endosomes than does Ab40.
Dynamin-DN reduced ISF Ab levels by over 60%. However,
washout of dynamin-DN caused a transient surge in ISF Ab levels.
This suggests that APP may have been retained on the cell sur-
face during inhibition of endocytosis and comprised a large
pool of substrate capable of generating Abwhen endocytosis re-
sumed. In the in vivo paradigm, for Ab production to be elevatedNeuron 58, 42–51, April 10, 2008 ª2008 Elsevier Inc. 47
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Generation
(A) Tg2576 mice were either treated with 200 mM
dynamin-DN for 12 hr or pretreated with 200 mM
dynamin-DN for 4 hr followed by dynamin-DN
and 10 mM TTX together for an additional 8 hr. Hip-
pocampal ISF Ab levels were measured by micro-
dialysis.
(B) Dynamin-DN reduced ISF Ab levels to 33.0% ±
3.2% of baseline over 12 hr (p < 0.0001), and
coadministration with TTX did not additionally
change Ab levels compared to dynamin-DN alone
(n = 4 per group).
(C) Mice were either treated with 10 mM TTX alone
for 12 hr or with TTX for 8 hr followed by TTX and
200 mM dynamin-DN together for an additional
4 hr. Ten micromolar TTX alone for 12 hr reduced
ISF Ab levels to 41.8% ± 3.2% of baseline (p <
0.0001, n = 8). When TTX was coadministered
with dynamin-DN, ISF Ab levels decreased to
30.0% ± 1.4% of baseline (p < 0.0001, n = 5).
The 7% difference between TTX and TTX with
dynamin-DN was significant (p < 0.05). Data
presented as mean ± SEM. *p < 0.05.when endocytosis resumed, much of the APP retained on the
plasma membrane must have remained as the full-length,
uncleaved protein.
Several studies have demonstrated that Ab, particularly oligo-
meric species, can modulate various aspects of synaptic trans-
mission (Hsieh et al., 2006; Shankar et al., 2007; Ting et al., 2007;
Townsend et al., 2006). Our studies demonstrate that inhibition
of endocytosis has no effect on spontaneous EEG activity or
evoked potentials in vivo. Interestingly, blocking endocytosis re-
duced ISF Ab levels by 70% but did not appear to modulate
transmission. Given that Ab levels were not reduced to zero, it
is possible that the remaining 30% of ISF Ab was sufficient to re-
tain Ab’s effect, if any, on synaptic transmission. It is also likely
that the majority of ISF Ab present in 3-month-old Tg2576 mice
is monomeric and not oligomeric Ab. Further studies are required
to address what role Ab has on synaptic activity in vivo.
The data suggest there are at least three cellular mechanisms
that contribute to ISF Ab production. First, a pathway that is syn-
aptic activity dependent (TTX sensitive) and endocytosis depen-
dent, which contributes to approximately 60% of ISF Ab levels in
Tg2576 mice. Second, a pool of ISF Ab that requires endocytosis
but is independent of synaptic activity. This pathway is respon-
sible for another 10% of ISF Ab levels. Interestingly, inhibition
of endocytosis does not reduce ISF Ab levels to zero. The re-
maining pool of Ab, comprising 30% of total ISF Ab levels, may
be the product of several mechanisms, including Ab produced
within the secretory pathway (Busciglio et al., 1993) or Ab diffus-
ing from brain areas that are not affected by dynamin-DN or TTX.
Alternatively, this last pool may be a factor of incomplete inhibi-
tion of endocytosis or some small contribution of altered Ab elim-
ination. These values provide rough estimates for each of these
pools and provide an interesting framework to consider the
various pathways that contribute to the overall pool of ISF Ab.
A source of 70% of ISF Ab in vivo is a tantalizing target for ther-48 Neuron 58, 42–51, April 10, 2008 ª2008 Elsevier Inc.apeutic development. While inhibiting all clathrin-mediated en-
docytosis is unlikely to be a feasible strategy for lowering extra-
cellular Ab levels, it may be possible to modulate individual
components of the endocytic machinery or synaptic transmis-
sion to selectively affect Ab generation.
Several molecules influence the rate and amount of APP endo-
cytosis. LRP1 expression increases the rate of APP endocytosis
from the plasma membrane, whereas LRP1b expression
Figure 7. Model of Synaptic-Dependent Release of Ab
(A) Depolarization of the synaptic terminal causes calcium influx leading to syn-
aptic vesicle release. (B) Synaptic vesicle membrane recycling from the cell
surface via clathrin-mediated endocytosis causes more APP to internalized
(C). Within endosomes, BACE and g-secretase cleave APP to produce Ab
(D), which is secreted from the neuron into the brain ISF (E).
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cent evidence also implicates another LDL-R family member,
LR11 or SorLa, in modulating APP trafficking through the endo-
somal compartment (Andersen et al., 2005; Dodson et al., 2006;
Offe et al., 2006; Rogaeva et al., 2007). LR11 overexpression in-
creases APP colocalization within the Golgi and reduces Ab gen-
eration in culture, whereas deletion of the LR11 gene in mice
increases brain Ab levels (Andersen et al., 2005). Given that sev-
eral LDL-R family members modulate Ab endocytosis, it will be
important to elucidate if and how these molecules affect synaptic
activity-dependent Ab generation.
While our studies do not directly assess where Ab is produced
or released, it is likely that Ab generation that is caused by events
within the synaptic terminal would occur at or near the synapse.
Kamenetz and colleagues demonstrated that neurons virally ex-
pressing APP can depress synaptic transmission in nearby neu-
rons (Kamenetz et al., 2003). This also suggests that Ab released
from a neuron might even be able to feed back to inhibit activity
within the same neuron. We have identified a mechanism of Ab
production and release near the synapse that is intimately asso-
ciated with synaptic activity. This phenomenon produces a situ-
ation whereby synaptically released Ab is positioned to modulate
synaptic activity. The conformation of Ab that is released follow-
ing synaptic activity will likely be a critical factor for modulation of
neurotransmission. For instance, Ab oligomers appear to be
much more potent at depressing synaptic transmission than
Ab monomers (Townsend et al., 2006). The Ab conformations
that are released at synapses and whether those Ab species
change with age or disease stage is unknown.
Synaptic activity appears to affect Ab levels in humans as well.
First, a fraction of patients with temporal lobe epilepsy develop
diffuse Ab deposits in seizure-prone brain regions as early as
30 years of age (Gouras et al., 1997; Mackenzie and Miller,
1994). Second, there are several links between stress, neuronal
activity, and AD. Individuals that are prone to psychological
distress are more likely to develop AD (Wilson et al., 2005; Wilson
et al., 2003). Also, plasma levels of the stress hormone cortisol
are correlated with the rate of dementia progression in patients
with AD (Csernansky et al., 2006). In APP-transgenic mice sub-
jected to restraint stress, ISF Ab levels are significantly higher
than control animals; however, the acute increase in Ab levels
is blocked in the absence of neuronal activity (Kang et al.,
2007). Final support for the idea of a casual link between synaptic
activity and Ab levels in humans comes from recent brain-imag-
ing studies. Brain regions that contain the most metabolic activ-
ity throughout life, and presumably have the highest levels of
neuronal activity, are also the regions most vulnerable to Ab
accumulation and aggregation in AD patients (Buckner et al.,
2005). In each of these cases, synaptic activity appears to play
a role in regulating Ab levels under physiologic conditions. We
now identify a cellular pathway, endocytosis, that likely links
synaptic activity and Ab production.
EXPERIMENTAL PROCEDURES
Animals
All experimental procedures involving animals were performed in accordance
with guidelines established by the Animal Studies Committee at WashingtonUniversity. We bred Tg2576+/ hemizygous mice (a generous gift from Dr. K.
Ashe, University of Minnesota) to wild-type C57Bl6/SJL mice (Taconic Farms,
Germantown, NY), then aged the Tg2576+/ offspring to 3–5 months for use in
experiments. Animals were screened for the Tg2576 transgene by PCR from
tail DNA. Three-month-old C57Bl6 mice were ordered from Jackson Labora-
tory (Bar Harbor, ME).
Compounds
All pharmacological agents were purchased from Sigma-Aldrich (St. Louis,
MO) unless otherwise noted. Dynamin dominant-negative (Dynamin-DN) in-
hibitory peptide (myristylated) and control scrambled peptide were purchased
from Tocris Biosciences (Ellisville, MO). The mGluR2/3 antagonist LY341495
and g-secretase inhibitor LY411575 were kind gifts from Darryle Schoepp
and Patrick May (Eli Lilly and Company, Indianapolis, IN). All compounds
were diluted in microdialysis perfusion buffer and administered via reverse
microdialysis, with the exception of LY411575, which was diluted in Mazola
corn oil and administered subcutaneously.
Ab ELISA
ISF Ab levels were assessed using sandwich ELISAs as described (Cirrito et al.,
2003). Briefly, to assess human Ab1-x, a central domain, mouse monoclonal
antibody (m266) was used to capture and a biotinylated N-terminal human
Ab-specific antibody (m3D6) was used to detect, followed by streptavidin-
poly-HRP-20 (Fitzgerald Industries, Concord, MA). Human Ab1-40 and human
Ab1-42 was assessed similar to Ab1-x; however, mouse monoclonal antibodies
m2G3 and m21F12, respectively, were used as coating antibodies. Murine
Abx-40 was assessed using an Ab40-specific mouse monoclonal antibody,
mHJ2, as a coating antibody and a biotinylated central domain antibody,
mHJ5.1, as the detecting antibody, followed by streptavidin-poly-HRP-40
(Fitzgerald Industries). All ELISA assays were developed using Super Slow
ELISA TMB (Sigma, St. Louis, MO) and absorbance read on a Bio-Tek
FL-600 plate reader (Winooski, VT) at 650 nm.
In Vivo AbMicrodialysis
In vivo microdialysis to assess brain ISF Ab1-x in the hippocampus of awake,
freely moving Tg2576 mice was performed similar to previously described
(Cirrito et al., 2003). This technique samples soluble molecules within the ex-
tracellular fluid that are smaller than 30 kDa, the molecular weight cut off of
the probe membrane. Ab capable of entering the probe has been dubbed
‘‘exchangeable Ab,’’ or ‘‘eAb’’ (Cirrito et al., 2003).
Under isoflurane volatile anesthetic, guide cannula (BR-style, Bioanalytical
Systems, Indianapolis, IN) were cemented into the left hippocampus (bregma
3.1 mm, 2.5 mm lateral to midline, and 1.2 mm below dura at a 12 angle).
Two-millimeter microdialysis probes were inserted through the guides so
that the membrane was contained entirely within the hippocampus (BR-2,
30 kDa MWCO membrane, Bioanalytical Systems). Microdialysis perfusion
buffer was artificial CSF containing 0.15% bovine serum albumin that was
filtered through a 0.1 mM membrane. Flow rate was a constant 1.0 ml/min. Sam-
ples were collected every 30–60 min with a refrigerated fraction collector into
polypropylene tubes and assessed for Ab by ELISA at the completion of each
experiment. Basal levels of ISF Ab were defined as the mean concentration of
Ab over 6–8 hr preceding drug treatment. For each animal, all Ab levels were
normalized to the basal Ab concentration. Once basal ISF Ab levels were
established, Tg2576 mice were treated with a variety of compounds by reverse
microdialysis. Compounds or vehicle were diluted in 0.15% BSA-aCSF
perfusion buffer.
Murine ISF Ab40 levels were assessed using a similar protocol, except longer
sample times of 12 hr at a 0.5 ml/min flow rate were necessary to concentrate
ISF samples. For each mouse, the basal concentration of Ab was established
over 12 hr of collection followed by 12 hr treatment with either dynamin-DN,
picrotoxin, or cotreatment with dynamin-DN and picrotoxin. In the latter group,
dynamin-DN was pretreated for 1 hr prior to cotreatment with picrotoxin.
EEG Recording
To record EEG activity, bipolar recording electrodes (Teflon-coated, stainless-
steel wire, 0.0055 inch coated OD, A-M Systems, Carlsborg, WA) were attached
to the shaft of the microdialysis guide cannula with Elmer’s Super-Fast EpoxyNeuron 58, 42–51, April 10, 2008 ª2008 Elsevier Inc. 49
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guide, so that the electrode tip was located at the center of the 2 mm microdial-
ysis membrane. EEG activity was assessed using a P511K A.C. Pre-amplifier
(Grass Instruments, Quincy, MA), digitized with a DigiData 1322A Data Ac-
quisition System (Axon Instruments, Union City, CA), and recorded digitally
using pClamp 9.2 (Axon Instruments). EEG amplitude standard deviation and
frequency power spectrum were assessed for 15 min epochs for 4 hr prior
treatment and during 4 hr of dynamin-DN treatment.
Evoked Field Potential Recordings
Microdialysis was performed as described previously; however, implant coor-
dinates were altered to coincide with optimized perforant pathway stimulation.
The stimulating electrode (model SNE-200X-35, Rhodes Medical, Summer-
land, CA) was implanted at bregma 4.3 mm, 2.9 mm lateral to midline, at
1.2–1.6 mm below dura. Recording electrodes were designed similar to
EEG recording electrodes except the electrode tips extended approximately
0.5 mm beyond the tip of the microdialysis probe. Guide cannula were inserted
at coordinates 2.5 mm, 1.3 mm lateral to midline, and 1.5–1.9 mm below
dura. The precise location of the recording and stimulating electrodes was op-
timized based on the fEPSP waveform produced during placement. Two bone
screws were used; one had a grounding wire attached. The cannula/electrode
assembly was then cemented to the skull using a binary dental cement (Bioa-
nalytical Systems). The DigiData 1322A and stimulus isolator (World Precision
Instruments, Sarasota, FL) were used to deliver evoked potentials.
Field EPSPs were evoked by a constant current stimulus (0.1 ms duration)
that produced a 50% max slope as determined by an input-output curve.
The slope of the initial fEPSP was assessed using pClamp version 9.2 soft-
ware. Single fEPSPs were assessed at a frequency of 0.017 Hz at various times
before and during drug treatments. In each animal, dynamin-DN was treated
by reverse microdialysis for 4 hr; then the perfusion buffer was changed to con-
tain TTX for 1 hr. Trains of fEPSPs were assessed at 1 Hz just prior to treatment
and after 4 hr of dynamin-DN administration.
Ab Elimination Half-Life
ISF Ab half-life was determined as described (Cirrito et al., 2003). Microdialysis
probes were inserted as described previously. Basal levels of ISF Ab were
established for 4 hr, followed by administration of dynamin-DN or vehicle via
reverse microdialysis for the remainder of the experiment. Four hours after
treatment began, LY411575, a potent, blood-brain barrier permeable g-secre-
tase inhibitor (Eli Lilly and Co, Indianapolis, IN), was administered subcutane-
ously at 3 mg/kg body weight in corn oil. Samples were collected every 30 min
for an additional 1 hr, then assessed for Ab1-x by ELISA.
Statistical Analysis
Data in figures represent mean ± SEM. All statistical analysis was performed
using Prism version 5.01 for Windows (GraphPad, San Diego, CA). Statistical
analysis was performed using a one-way ANOVA with Bonferroni post-test.
Values were accepted as significant if p% 0.05.
SUPPLEMENTAL DATA
The Supplemental Data for this article can be found online at http://www.
neuron.org/cgi/content/full/58/1/42/DC1/.
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